Are Biotech Stocks Overvalued and in a Bubble?
March 26 -- Clearbridge Investments Health Care Analyst Marshall Gordon discusses the performance of biotech stocks. Bloomberg’s Drew Armstrong also speaks on “Market Makers.”
March 26 -- Clearbridge Investments Health Care Analyst Marshall Gordon discusses the performance of biotech stocks. Bloomberg’s Drew Armstrong also speaks on “Market Makers.”